Novo Nordisk A/S (NYSE:NVO) Cut to “Hold” at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S (NYSE:NVO) from a buy rating to a hold rating in a research note issued to investors on Monday, MarketBeat.com reports.

NVO has been the topic of a number of other research reports. HSBC reiterated a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, January 22nd. TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Finally, Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Six research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus target price of $56.07.

Novo Nordisk A/S Trading Down 1.2%

NYSE:NVO opened at $38.13 on Monday. The stock has a market cap of $170.24 billion, a price-to-earnings ratio of 10.99 and a beta of 0.67. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. Novo Nordisk A/S has a 1 year low of $37.65 and a 1 year high of $91.90. The business has a fifty day moving average of $53.16 and a 200-day moving average of $53.04.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 23.63%.

Institutional Trading of Novo Nordisk A/S

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quotient Wealth Partners LLC raised its holdings in shares of Novo Nordisk A/S by 2.0% during the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after acquiring an additional 177 shares during the period. Certuity LLC grew its position in Novo Nordisk A/S by 3.6% during the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after purchasing an additional 177 shares in the last quarter. Beacon Financial Group raised its stake in Novo Nordisk A/S by 4.3% during the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after purchasing an additional 178 shares during the period. Oakworth Capital Inc. raised its stake in Novo Nordisk A/S by 41.6% during the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after purchasing an additional 182 shares during the period. Finally, True North Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after purchasing an additional 199 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Strategic deal to pursue oral biologic delivery — Novo agreed to partner with Vivtex in an up-to-$2.1 billion arrangement to develop next‑generation oral medicines for obesity and diabetes, which could expand addressable markets if the technology works. WSJ: Novo Nordisk, Vivtex to Develop Obesity Drugs in Deal Valued at Up to $2.1 Billion
• Positive Sentiment: Promising Phase 2 China data for triple‑agonist UBT251 — a partner trial reported up to 19.7% mean weight loss, supporting Novo’s pipeline diversification beyond semaglutide. This helps offset concern about any single program. Reuters: Novo Nordisk, United Biotechnology obesity drug trial shows 19.7% weight loss
• Positive Sentiment: Short interest fell sharply in February — a nearly 15% drop reduces near-term short‑covering risk and signals some reduced bearish bets against the stock. (Short interest data summary)
• Neutral Sentiment: Commentary framing the sell-off as a potential deep-value opportunity — some analysts and outlets argue the decline creates an entry point, while others caution that structural challenges remain. Benzinga: Novo Nordisk’s 40% Fall May Be Creating A Deep-Value Moment
• Negative Sentiment: Planned U.S. list‑price cuts for Ozempic and Wegovy (up to ~50%) will likely pressure revenue and margins in 2027 and beyond, even if they shore up access and volumes. CNBC: Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S.
• Negative Sentiment: CagriSema trial missed non‑inferiority versus Eli Lilly’s Zepbound, triggering analyst downgrades and a reassessment of Novo’s competitive positioning post‑semaglutide. That clinical setback is a primary driver of the recent sell‑off and lower forecasts. CNBC: Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades
• Negative Sentiment: Multiple sell‑side downgrades and price‑target cuts (including Deutsche Bank/Kepler) are amplifying selling pressure and reducing near‑term analyst support. (Downgrade reports)
• Negative Sentiment: Shareholder litigation inquiry announced by the Schall Law Firm alleging possible misleading statements — adds legal risk and potential distraction. GlobeNewsWire: NVO Investors Have Opportunity to Join Fraud Investigation

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.